-transparent.png){kind=logo}
The pathway of 3,4-dihydroxyphenylalanine undergoing metabolism via transamination and subsequent oxidative rearrangement to 2,4,5-trihydroxy-phenylacetate was investigated. 3-Methoxytyrosine does not pursue an identical course, since its corresponding keto acid is not subject to action of p-hydroxy-phenylpyruvate hydroxylase. The radiochemical synthesis of 3-methoxy-4-hydroxy[carboxy-14C] pyruvate was accomplished. This metabolite was used to demonstrate that this keto acid does not proceed through oxidative rearrangement both in vitro and in vivo. The keto acid was found to be a competitive inhibitor of the hydroxylase and can help account for some of the metabolites observed in the urine of patients treated with 3,4-dihydroxyphenylalanine.
J H Fellman, and
G H Wada, and
E S Roth
May 1957,
The Journal of biological chemistry,
J H Fellman, and
G H Wada, and
E S Roth
January 1988,
L'Encephale,
J H Fellman, and
G H Wada, and
E S Roth
January 1985,
Endocrinologie,
J H Fellman, and
G H Wada, and
E S Roth
May 1977,
The American journal of psychiatry,
J H Fellman, and
G H Wada, and
E S Roth
December 1959,
Biochimica et biophysica acta,
J H Fellman, and
G H Wada, and
E S Roth
July 1983,
Analytical chemistry,
J H Fellman, and
G H Wada, and
E S Roth
February 1968,
Experientia,
J H Fellman, and
G H Wada, and
E S Roth
September 1964,
Acta endocrinologica,
J H Fellman, and
G H Wada, and
E S Roth
August 1957,
Biochimica et biophysica acta,
J H Fellman, and
G H Wada, and
E S Roth
July 1974,
Arzneimittel-Forschung,
